Moreover, ARID1A mutant tumours have been shown to demonstrate activation of the immune checkpoint pathway and sensitization to the PD-1/PD-L1 checkpoint blockade in ovarian cancer in in vivo mouse models. Here, ARID1A is linked to ovarian cancer.